{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:45:12Z","timestamp":1787003112600,"version":"build-2736575974"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T00:00:00Z","timestamp":1671148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T00:00:00Z","timestamp":1671148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Two malaria parasite species,\n                    <jats:italic>Plasmodium falciparum<\/jats:italic>\n                    (\n                    <jats:italic>Pf<\/jats:italic>\n                    ) and\n                    <jats:italic>P. vivax<\/jats:italic>\n                    (\n                    <jats:italic>Pv<\/jats:italic>\n                    ) are responsible for most of the disease burden caused by malaria. Vaccine development against this disease has focused mainly on\n                    <jats:italic>Pf<\/jats:italic>\n                    . Whole-sporozoite (WSp) vaccination, targeting pre-erythrocytic (PE) parasite stages, is a promising strategy for immunization against malaria and several\n                    <jats:italic>Pf<\/jats:italic>\n                    WSp-based vaccine candidates are currently undergoing clinical evaluation. In contrast, no WSp candidates have been developed for\n                    <jats:italic>Pv<\/jats:italic>\n                    , mainly due to constraints in the production of\n                    <jats:italic>Pv<\/jats:italic>\n                    sporozoites in the laboratory. Recently, we developed a novel approach for WSp vaccination against\n                    <jats:italic>Pf<\/jats:italic>\n                    based on the use of transgenic rodent\n                    <jats:italic>P. berghei<\/jats:italic>\n                    (\n                    <jats:italic>Pb<\/jats:italic>\n                    ) sporozoites expressing immunogens of this human-infective parasite. We showed that this platform can be used to deliver PE\n                    <jats:italic>Pf<\/jats:italic>\n                    antigens, eliciting both targeted humoral responses and cross-species cellular immune responses against\n                    <jats:italic>Pf<\/jats:italic>\n                    . Here we explored this WSp platform for the delivery of\n                    <jats:italic>Pv<\/jats:italic>\n                    antigens. As the\n                    <jats:italic>Pv<\/jats:italic>\n                    circumsporozoite protein (CSP) is a leading vaccine candidate antigen, we generated a transgenic\n                    <jats:italic>Pb<\/jats:italic>\n                    parasite,\n                    <jats:italic>Pb<\/jats:italic>\n                    viVac, that, in addition to its endogenous\n                    <jats:italic>Pb<\/jats:italic>\n                    CSP, expresses\n                    <jats:italic>Pv<\/jats:italic>\n                    CSP under the control of a strictly PE promoter. Immunofluorescence microscopy analyses confirmed that both the\n                    <jats:italic>Pb<\/jats:italic>\n                    CSP and the\n                    <jats:italic>Pv<\/jats:italic>\n                    CSP antigens are expressed in\n                    <jats:italic>Pb<\/jats:italic>\n                    viVac sporozoites and liver stages and that\n                    <jats:italic>Pb<\/jats:italic>\n                    viVac sporozoite infectivity of hepatic cells is similar to that of its wild-type\n                    <jats:italic>Pb<\/jats:italic>\n                    counterpart. Immunization of mice with\n                    <jats:italic>Pb<\/jats:italic>\n                    viVac sporozoites elicits the production of anti-\n                    <jats:italic>Pv<\/jats:italic>\n                    CSP antibodies that efficiently recognize and bind to\n                    <jats:italic>Pv<\/jats:italic>\n                    sporozoites. Our results warrant further development and evaluation of\n                    <jats:italic>Pb<\/jats:italic>\n                    viVac as a surrogate for WSp vaccination against\n                    <jats:italic>Pv<\/jats:italic>\n                    malaria.\n                  <\/jats:p>","DOI":"10.1038\/s41541-022-00585-8","type":"journal-article","created":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T00:06:06Z","timestamp":1671149166000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["A genetically modified Plasmodium berghei parasite as a surrogate for whole-sporozoite vaccination against P. vivax malaria"],"prefix":"10.1038","volume":"7","author":[{"given":"Diana","family":"Moita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa G.","family":"Maia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Duarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9763-8857","authenticated-orcid":false,"given":"Carolina M.","family":"Andrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1108-0961","authenticated-orcid":false,"given":"In\u00eas S.","family":"Albuquerque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankit","family":"Dwivedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6502-7026","authenticated-orcid":false,"given":"Joana C.","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2347-5581","authenticated-orcid":false,"given":"Lilia","family":"Gonz\u00e1lez-C\u00e9ron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6410-6205","authenticated-orcid":false,"given":"Chris J.","family":"Janse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6562-5325","authenticated-orcid":false,"given":"Ant\u00f3nio M.","family":"Mendes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1746-6029","authenticated-orcid":false,"given":"Miguel","family":"Prud\u00eancio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,16]]},"reference":[{"key":"585_CR1","first-page":"951","volume":"6","author":"Geneva: World Health Organization.","year":"2021","unstructured":"Geneva: World Health Organization. World Malar. Rep. 2021. Angew. Chem. Int. Ed. 6, 951\u2013952 (2021).","journal-title":"World Malar. Rep. 2021. Angew. Chem. Int. Ed."},{"key":"585_CR2","doi-asserted-by":"publisher","unstructured":"White, N. J. Malaria. Manson\u2019s Tropical Infectious Diseases 532-600.e1 (2014) https:\/\/doi.org\/10.1016\/B978-0-7020-5101-2.00044-3.","DOI":"10.1016\/B978-0-7020-5101-2.00044-3"},{"key":"585_CR3","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1097\/QCO.0b013e32832f14c1","volume":"22","author":"RN Price","year":"2009","unstructured":"Price, R. N., Douglas, N. M. & Anstey, N. M. New developments in Plasmodium vivax malaria: Severe disease and the rise of chloroquine resistance. Curr. Opin. Infect. Dis. 22, 430\u2013435 (2009).","journal-title":"Curr. Opin. Infect. Dis."},{"key":"585_CR4","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.cell.2016.07.055","volume":"167","author":"AF Cowman","year":"2016","unstructured":"Cowman, A. F., Healer, J., Marapana, D. & Marsh, K. Malaria: Biology and Disease. Cell 167, 610\u2013624 (2016).","journal-title":"Cell"},{"key":"585_CR5","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/nm.3073","volume":"19","author":"LH Miller","year":"2013","unstructured":"Miller, L. H., Ackerman, H. C., Su, X. & Wellems, T. E. Malaria biology and disease pathogenesis: insights for new treatments. Nat. Med. 19, 156\u2013167 (2013).","journal-title":"Nat. Med."},{"key":"585_CR6","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1038\/nrmicro1529","volume":"4","author":"M Prud\u00eancio","year":"2006","unstructured":"Prud\u00eancio, M., Rodriguez, A. & Mota, M. M. The silent path to thousands of merozoites: The Plasmodium liver stage. Nat. Rev. Microbiol. 4, 849\u2013856 (2006).","journal-title":"Nat. Rev. Microbiol."},{"key":"585_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41541-020-0196-3","volume":"5","author":"PE Duffy","year":"2020","unstructured":"Duffy, P. E. & Patrick Gorres, J. Malaria vaccines since 2000: progress, priorities, products. NPJ Vaccines. 5, 1\u20139 (2020).","journal-title":"NPJ Vaccines."},{"key":"585_CR8","doi-asserted-by":"publisher","first-page":"e156588","DOI":"10.1172\/JCI156588","volume":"132","author":"F Zavala","year":"2022","unstructured":"Zavala, F. RTS, S: the first malaria vaccine. J. Clin. Invest 132, e156588 (2022).","journal-title":"J. Clin. Invest"},{"key":"585_CR9","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(15)60721-8","volume":"386","author":"RTS, S. C. T. P.","year":"2015","unstructured":"RTS, S. C. T. P. Efficacy and safety of RTS,S\/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: Final results of a phase 3, individually randomised, controlled trial. Lancet 386, 31\u201345 (2015).","journal-title":"Lancet"},{"key":"585_CR10","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1126\/science.1241800","volume":"341","author":"R Seder","year":"2013","unstructured":"Seder, R. et al. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science 341, 1359\u20131365 (2013).","journal-title":"Science"},{"key":"585_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/scitranslmed.aaz5629","volume":"12","author":"M Roestenberg","year":"2020","unstructured":"Roestenberg, M. et al. A double-blind, placebo-controlled phase 1\/2a trial of the genetically attenuated malaria vaccine PfSPZ-GA1. Sci. Transl. Med. 12, 1\u201310 (2020).","journal-title":"Sci. Transl. Med."},{"key":"585_CR12","first-page":"445","volume":"542","author":"B Mordm\u00fcller","year":"2017","unstructured":"Mordm\u00fcller, B. et al. Sterile protection against human malaria by chemoattenuated PfSPZ vaccine. Nat. Publ. Group. 542, 445\u2013449 (2017).","journal-title":"Nat. Publ. Group."},{"key":"585_CR13","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.4269\/ajtmh.21-0942","volume":"106","author":"SA Jongo","year":"2022","unstructured":"Jongo, S. A. et al. Multi-Dose Priming Regimens of PfSPZ Vaccine: Safety and Efficacy against Controlled Human Malaria Infection in Equatoguinean Adults. Am. J. Trop. Med Hyg. 106, 1215\u20131226 (2022).","journal-title":"Am. J. Trop. Med Hyg."},{"key":"585_CR14","doi-asserted-by":"publisher","first-page":"e1009594","DOI":"10.1371\/journal.ppat.1009594","volume":"17","author":"SC Murphy","year":"2021","unstructured":"Murphy, S. C. et al. PfSPZ-CVac efficacy against malaria increases from 0% to 75% when administered in the absence of erythrocyte stage parasitemia: A randomized, placebo-controlled trial with controlled human malaria infection. PLoS Pathog. 17, e1009594 (2021).","journal-title":"PLoS Pathog"},{"key":"585_CR15","doi-asserted-by":"publisher","first-page":"e0004423","DOI":"10.1371\/journal.pntd.0004423","volume":"10","author":"JW Bennett","year":"2016","unstructured":"Bennett, J. W. et al. Phase 1\/2a Trial of Plasmodium vivax Malaria Vaccine Candidate VMP001\/AS01B in Malaria-Naive Adults: Safety, Immunogenicity, and Efficacy. PLoS Negl. Trop. Dis. 10, e0004423 (2016).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"585_CR16","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1186\/s12936-018-2456-5","volume":"17","author":"M Berm\u00fadez","year":"2018","unstructured":"Berm\u00fadez, M., Moreno-P\u00e9rez, D. A., Ar\u00e9valo-Pinz\u00f3n, G., Curtidor, H. & Patarroyo, M. A. Plasmodium vivax in vitro continuous culture: The spoke in the wheel. Malaria Journal 17, 301 (2018).","journal-title":"Malaria Journal"},{"key":"585_CR17","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41541-018-0068-2","volume":"3","author":"AM Mendes","year":"2018","unstructured":"Mendes, A. M. et al. A Plasmodium berghei sporozoite-based vaccination platform against human malaria. NPJ Vaccines 3, 33 (2018).","journal-title":"NPJ Vaccines"},{"key":"585_CR18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41541-017-0041-5","volume":"3","author":"AM Mendes","year":"2018","unstructured":"Mendes, A. M. et al. Pre-clinical evaluation of a P. berghei-based whole-sporozoite malaria vaccine candidate. NPJ Vaccines. 3, 1\u201312 (2018).","journal-title":"NPJ Vaccines."},{"key":"585_CR19","doi-asserted-by":"publisher","first-page":"eaay2578","DOI":"10.1126\/scitranslmed.aay2578","volume":"12","author":"IJ Reuling","year":"2020","unstructured":"Reuling, I. J. et al. An open-label phase 1\/2a trial of a genetically modified rodent malaria parasite for immunization against Plasmodium falciparum malaria. Sci. Transl. Med. 12, eaay2578 (2020).","journal-title":"Sci. Transl. Med"},{"key":"585_CR20","doi-asserted-by":"publisher","first-page":"102411","DOI":"10.1016\/j.parint.2021.102411","volume":"84","author":"A Reyes-Sandoval","year":"2021","unstructured":"Reyes-Sandoval, A. Plasmodium vivax pre-erythrocytic vaccines. Parasitol Int. 84, 102411 (2021).","journal-title":"Parasitol Int"},{"key":"585_CR21","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1080\/14760584.2021.1880898","volume":"20","author":"SL De","year":"2021","unstructured":"De, S. L., Ntumngia, F. B., Nicholas, J. & Adams, J. H. Progress towards the development of a P. vivax vaccine. Expert Rev. Vaccines 20, 97\u2013112 (2021).","journal-title":"Expert Rev. Vaccines"},{"key":"585_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12936-020-03366-7","volume":"19","author":"TC V\u00f5","year":"2020","unstructured":"V\u00f5, T. C. et al. Genetic polymorphism and natural selection of circumsporozoite protein in Myanmar Plasmodium vivax. Malar. J. 19, 1\u201317 (2020).","journal-title":"Malar. J."},{"key":"585_CR23","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.gene.2013.01.003","volume":"518","author":"S Dias","year":"2013","unstructured":"Dias, S., Wickramarachchi, T., Sahabandu, I., Escalante, A. A. & Udagama, P. V. Population genetic structure of the Plasmodium vivax circumsporozoite protein (Pvcsp) in Sri Lanka. Gene 518, 381\u2013387 (2013).","journal-title":"Gene"},{"key":"585_CR24","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.meegid.2010.01.006","volume":"10","author":"A Patil","year":"2010","unstructured":"Patil, A., Orjuela-S\u00e1nchez, P., da Silva-Nunes, M. & Ferreira, M. U. Evolutionary dynamics of the immunodominant repeats of the Plasmodium vivax malaria-vaccine candidate circumsporozoite protein (CSP). Infect. Genet. Evolution. 10, 298\u2013303 (2010).","journal-title":"Infect. Genet. Evolution."},{"key":"585_CR25","doi-asserted-by":"publisher","first-page":"e29289","DOI":"10.1371\/journal.pone.0029289","volume":"6","author":"JW Lin","year":"2011","unstructured":"Lin, J. W. et al. A novel \u2018Gene Insertion\/Marker Out\u2019 (GIMO) method for transgene expression and gene complementation in rodent malaria parasites. PLoS One 6, e29289 (2011).","journal-title":"PLoS One"},{"key":"585_CR26","doi-asserted-by":"publisher","unstructured":"Mueller, A.-K. et al. Plasmodium liver stage developmental arrest by depletion of a protein at the parasite-host interface. www.pnas.orgcgihttps:\/\/doi.org\/10.1073\/pnas.0408442102 (2005).","DOI":"10.1073\/pnas.0408442102"},{"key":"585_CR27","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/nm.4110","volume":"22","author":"AS Ishizuka","year":"2016","unstructured":"Ishizuka, A. S. et al. Protection against malaria at 1 year and immune correlates following PfSPZ vaccination. Nat. Med 22, 614\u2013623 (2016).","journal-title":"Nat. Med"},{"key":"585_CR28","unstructured":"Global Malaria Progamme. Control and Elimination of Plamodium Vivax Malaria - A Technical Brief. Control and Elimination of Plamodium Vivax Malaria - A Technical Brief 1\u201364 (2015)."},{"key":"585_CR29","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1128\/IAI.01667-06","volume":"75","author":"A Yadava","year":"2007","unstructured":"Yadava, A. et al. A novel chimeric Plasmodium vivax circumsporozoite protein induces biologically functional antibodies that recognize both VK210 and VK247 sporozoites. Infect. Immun. 75, 1177\u20131185 (2007).","journal-title":"Infect. Immun."},{"key":"585_CR30","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1038\/s41467-022-29226-3","volume":"13","author":"M Ar\u00e9valo-Herrera","year":"2022","unstructured":"Ar\u00e9valo-Herrera, M. et al. Randomized clinical trial to assess the protective efficacy of a Plasmodium vivax CS synthetic vaccine. Nat. Commun. 13, 1603 (2022).","journal-title":"Nat. Commun"},{"key":"585_CR31","doi-asserted-by":"publisher","first-page":"e00479","DOI":"10.1128\/IAI.00479-17","volume":"86","author":"DI Stanisic","year":"2018","unstructured":"Stanisic, D. I., McCarthy, J. S. & Good, M. F. Controlled human malaria infection: Applications, advances, and challenges. Infect. Immun. 86, e00479\u201317 (2018).","journal-title":"Infect. Immun"},{"key":"585_CR32","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.pt.2016.11.001","volume":"33","author":"RO Payne","year":"2017","unstructured":"Payne, R. O., Griffin, P. M., McCarthy, J. S. & Draper, S. J. Plasmodium vivax Controlled Human Malaria Infection \u2013 Progress and Prospects. Trends Parasitol. 33, 141\u2013150 (2017).","journal-title":"Trends Parasitol."},{"key":"585_CR33","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1006\/expr.1993.1069","volume":"77","author":"BJ Sina","year":"1993","unstructured":"Sina, B. J., do Rosario, V. E., Woollett, G., Sakhuja, K. & Hollingdale, M. R. Plasmodium falciparum Sporozoite Immunization Protects against Plasmodium berghei Sporozoite Infection. Exp. Parasitol. 77, 129\u2013135 (1993).","journal-title":"Exp. Parasitol."},{"key":"585_CR34","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1111\/j.1365-3024.2007.00976.x","volume":"29","author":"M Sedegah","year":"2007","unstructured":"Sedegah, M., Weiss, W. W. & Hoffman, S. L. Cross-protection between attenuated Plasmodium berghei and P. yoelii sporozoites. Parasite Immunol. 29, 559\u2013565 (2007).","journal-title":"Parasite Immunol."},{"key":"585_CR35","doi-asserted-by":"publisher","first-page":"e107764","DOI":"10.1371\/journal.pone.0107764","volume":"9","author":"AR Noe","year":"2014","unstructured":"Noe, A. R. et al. A full-length Plasmodium falciparum recombinant circumsporozoite protein expressed by Pseudomonas fluorescens platform as a Malaria vaccine candidate. PLoS One. 9, e107764 (2014).","journal-title":"PLoS One"},{"key":"585_CR36","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1128\/IAI.01108-12","volume":"81","author":"K Kastenm\u00fcller","year":"2013","unstructured":"Kastenm\u00fcller, K. et al. Full-length plasmodium falciparum circumsporozoite protein administered with long-chain poly(I\u00b7C) or the toll-like receptor 4 agonist glucopyranosyl lipid adjuvant-stable emulsion elicits potent antibody and CD4+ T cell immunity and protection in mice. Infect. Immun. 81, 789\u2013800 (2013).","journal-title":"Infect. Immun."},{"key":"585_CR37","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1093\/infdis\/jis220","volume":"205","author":"A Yadava","year":"2012","unstructured":"Yadava, A., Nurmukhambetova, S., Pichugin, A. V. & Lumsden, J. M. Cross-species immunity following immunization with a circumsporozoite protein-based vaccine for malaria. J. Infect. Dis. 205, 1456\u20131463 (2012).","journal-title":"J. Infect. Dis."},{"key":"585_CR38","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.vaccine.2008.09.097","volume":"27","author":"SE Bongfen","year":"2009","unstructured":"Bongfen, S. E. et al. The N-terminal domain of Plasmodium falciparum circumsporozoite protein represents a target of protective immunity. Vaccine 27, 328\u2013335 (2009).","journal-title":"Vaccine"},{"key":"585_CR39","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1146\/annurev.iy.11.040193.003351","volume":"11","author":"EH Nardin","year":"1993","unstructured":"Nardin, E. H. & Nussenzweig, R. S. T Cell responses to pre-erythrocytic stages of malaria: Role in protection and Vaccine development against pre-erythrocytic stages. Annu. Rev. Immunol. 11, 687\u2013727 (1993).","journal-title":"Annu. Rev. Immunol."},{"key":"585_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2021.775659","volume":"12","author":"L Kurtovic","year":"2021","unstructured":"Kurtovic, L., Drew, D. R., Dent, A. E., Kazura, J. W. & Beeson, J. G. Antibody Targets and Properties for Complement-Fixation Against the Circumsporozoite Protein in Malaria Immunity. Front Immunol. 12, 1\u201312 (2021).","journal-title":"Front Immunol."},{"key":"585_CR41","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/j.vaccine.2020.12.055","volume":"39","author":"S Chaudhury","year":"2021","unstructured":"Chaudhury, S. et al. Breadth of humoral immune responses to the C-terminus of the circumsporozoite protein is associated with protective efficacy induced by the RTS,S malaria vaccine. Vaccine 39, 968\u2013975 (2021).","journal-title":"Vaccine"},{"key":"585_CR42","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1084\/jem.20101488","volume":"208","author":"A Coppi","year":"2011","unstructured":"Coppi, A. et al. The malaria circumsporozoite protein has two functional domains, each with distinct roles as sporozoites journey from mosquito to mammalian host. J. Exp. Med. 208, 341\u2013356 (2011).","journal-title":"J. Exp. Med."},{"key":"585_CR43","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1126\/science.2672336","volume":"245","author":"R Rosenberg","year":"1989","unstructured":"Rosenberg, R. et al. Circumsporozoite Protein Heterogeneity in the Human Malaria Parasite Plasmodium vivax. Science 245, 973\u2013976 (1989).","journal-title":"Science"},{"key":"585_CR44","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1038\/ng.2373","volume":"44","author":"DE Neafsey","year":"2012","unstructured":"Neafsey, D. E. et al. The malaria parasite Plasmodium vivax exhibits greater genetic diversity than Plasmodium falciparum. Nat. Genet. 44, 1046\u20131050 (2012).","journal-title":"Nat. Genet."},{"key":"585_CR45","doi-asserted-by":"publisher","first-page":"17928","DOI":"10.1038\/s41598-021-96986-1","volume":"11","author":"AM Gimenez","year":"2021","unstructured":"Gimenez, A. M. et al. A universal vaccine candidate against Plasmodium vivax malaria confers protective immunity against the three PvCSP alleles. Sci. Rep. 11, 17928 (2021).","journal-title":"Sci. Rep"},{"key":"585_CR46","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.3389\/fimmu.2017.01275","volume":"8","author":"AM Gimenez","year":"2017","unstructured":"Gimenez, A. M. et al. Vaccine containing the three allelic variants of the Plasmodium vivax circumsporozoite antigen induces protection in mice after challenge with a transgenic rodent malaria parasite. Front. Immunol. 8, 1275 (2017).","journal-title":"Front. Immunol"},{"key":"585_CR47","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/978-1-4939-2815-6_21","volume":"1325","author":"AM Salman","year":"2015","unstructured":"Salman, A. M. et al. Generation of transgenic rodent malaria parasites expressing human malaria parasite proteins. Methods Mol. Biol. 1325, 257\u2013286 (2015).","journal-title":"Methods Mol. Biol"},{"key":"585_CR48","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1128\/IAI.01187-13","volume":"82","author":"K Bauza","year":"2014","unstructured":"Bauza, K. et al. Efficacy of a Plasmodium vivax malaria vaccine using ChAd63 and modified vaccinia ankara expressing thrombospondin-related anonymous protein as assessed with transgenic Plasmodium berghei parasites. Infect. Immun. 82, 1277\u20131286 (2014).","journal-title":"Infect. Immun."},{"key":"585_CR49","doi-asserted-by":"publisher","unstructured":"Grimberg, B. T. et al. Plasmodium vivax Invasion of Human Erythrocytes Inhibited by Antibodies Directed against the Duffy Binding Protein. (2007) https:\/\/doi.org\/10.1371\/journal.pmed.","DOI":"10.1371\/journal.pmed"},{"key":"585_CR50","doi-asserted-by":"publisher","first-page":"6014","DOI":"10.1016\/j.vaccine.2010.06.100","volume":"28","author":"AM Blagborough","year":"2010","unstructured":"Blagborough, A. M., Yoshida, S., Sattabongkot, J., Tsuboi, T. & Sinden, R. E. Intranasal and intramuscular immunization with Baculovirus Dual Expression System-based Pvs25 vaccine substantially blocks Plasmodium vivax transmission. Vaccine 28, 6014\u20136020 (2010).","journal-title":"Vaccine"},{"key":"585_CR51","doi-asserted-by":"publisher","first-page":"7452","DOI":"10.1016\/j.vaccine.2015.09.096","volume":"33","author":"TL Richie","year":"2015","unstructured":"Richie, T. L. et al. Progress with Plasmodium falciparum sporozoite (PfSPZ)-based malaria vaccines. Vaccine 33, 7452\u20137461 (2015).","journal-title":"Vaccine"},{"key":"585_CR52","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1006\/expr.1998.4334","volume":"90","author":"L Gonzalez-Ceron","year":"1998","unstructured":"Gonzalez-Ceron, L. et al. Plasmodium vivax: A Monoclonal Antibody Recognizes a Circumsporozoite Protein Precursor on the Sporozoite Surface. Exp. Parasitol. 90, 203\u201311 (1998).","journal-title":"Exp. Parasitol"},{"key":"585_CR53","doi-asserted-by":"publisher","first-page":"46482","DOI":"10.1038\/srep46482","volume":"7","author":"AM Salman","year":"2017","unstructured":"Salman, A. M. et al. Rational development of a protective P. vivax vaccine evaluated with transgenic rodent parasite challenge models. Sci. Rep. 7, 46482 (2017).","journal-title":"Sci. Rep"},{"key":"585_CR54","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.4049\/jimmunol.1700893","volume":"199","author":"V Jurtz","year":"2017","unstructured":"Jurtz, V. et al. NetMHCpan-4.0: Improved Peptide\u2013MHC Class I Interaction Predictions Integrating Eluted Ligand and Peptide Binding Affinity Data. J. Immunol. 199, 3360\u20133368 (2017).","journal-title":"J. Immunol."},{"key":"585_CR55","doi-asserted-by":"publisher","first-page":"D784","DOI":"10.1093\/nar\/gku1166","volume":"43","author":"FF Gonz\u00e1lez-Galarza","year":"2015","unstructured":"Gonz\u00e1lez-Galarza, F. F. et al. Allele frequency net 2015 update: New features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations. Nucl. Acids Res. 43, D784\u2013D788 (2015).","journal-title":"Nucl. Acids Res."}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00585-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00585-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00585-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T01:03:32Z","timestamp":1671152612000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00585-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,16]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["585"],"URL":"https:\/\/doi.org\/10.1038\/s41541-022-00585-8","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,16]]},"assertion":[{"value":"28 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.M.M. and M.P. are inventors on a patent or patent application issued, allowed or field internationally, covering parts of this work. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"163"}}